SPA™ highlighted as an innovative solubility measurement technology addressing the gap at the discovery-development interface.

Researchers at Eli Lilly and Company, AstraZeneca, Novartis, and Pfizer recently highlighted the critical role of solubility measurement in drug discovery and development, addressing the current gap at the discovery-development interface.

“Solubility is a key physicochemical property for the success of any drug candidate” but “an artificial boundary can exist at the discovery-development interface”.

The Solubility Company is proud to have our SPA™ technology mentioned as an innovative technology addressing this gap, especially in terms of solid-state relevant solubility measurement.

Contact Us for more information on how your drug development projects can benefit from access to more relevant data!

Check out the full article here:
Link to Paper

Recent Posts

Leave a Reply

Your email address will not be published. Required fields are marked *